Literature DB >> 233668

Relationship between thyroid status and Graves' disease-specific immunoglobulins.

H Schleusener, P Kotulla, R Finke, H Sörje, H Meinhold, F Adlkofer, K W Wenzel.   

Abstract

The prevalence of TSI in Graves' disease was investigated with a radioligand receptor assay using human thyroid membranes and highly purified labeled porcine TSH or bovine TSH in 110 patients before treatment and in 39 patients after successful treatment with antithyroid drugs. In 11 patients, the assay was performed before, during, and after therapy. The results in the radioligand receptor assay were compared to thyroid function tests (TRH test, free T4 index, serum %3 level, and thyroid suppression test). Normal IgG inhibits nonspecifically, but dose dependently, the binding of [125I]TSH to thyroid membranes. IgG samples from patients were only considered to be positive if they reduced the binding of the labeled hormone below the mean value minus 2 SD of the controls. TSI activity was found in 50% of the patients with untreated diffuse toxic goiter, in 3 out of 27 cases who regained suppressible thyroid function, and in 5 out of 12 cases who were off therapy for more than 6 weeks and showed normal TRH tests and normal hormone levels but in whom the suppression test was not performed. Our data cannot prove the hypothesis that only humoral antibodies are responsible for the thyroid stimulation in Graves' disease, but of course they cannot exclude it; furthermore, they suggest the existence of antibodies which bind to the human thyroid cell membrane without necessarily stimulating thyroid cellular activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 233668     DOI: 10.1210/jcem-47-2-379

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  TSH-receptor antibodies, HLA B8 and thyroid autoantibodies in patients with Graves' disease in therapeutically induced euthyroidism.

Authors:  G Schernthaner; H Ludwig; H Schleusener; R Finke; P Kotulla; W R Mayr
Journal:  Experientia       Date:  1979-10-15

Review 2.  [Cell receptor defects as the cause of endocrine and metabolic diseases (author's transl)].

Authors:  W Gerok
Journal:  Klin Wochenschr       Date:  1979-06-15

3.  Radioligand receptor assay for TSH and TSH-binding-inhibiting antibodies using solubilized TSH-receptor.

Authors:  P Kotulla; C Kostner; H Schleusener
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

4.  Production, isolation, and characterization of rabbit anti-idiotypic antibodies directed against human antithyrotrophin receptor antibodies.

Authors:  J R Baker; Y G Lukes; K D Burman
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

5.  10 years experience with consecutive measurement of thyrotropin binding inhibiting antibodies (TBIAb).

Authors:  J Hensen; P Kotulla; R Finke; K Badenhoop; K Koppenhagen; H Meinhold; H Schleusener
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

6.  Partial characterization and clinical correlation of circulating human immunoglobulins directed against thyrotrophin binding sites in guinea pig fat cell membranes. Development of a direct enzyme immunoassay.

Authors:  J R Baker; Y G Lukes; R C Smallridge; M Berger; K D Burman
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

7.  Solubilized TSH-receptor: its usefulness for the radioligand receptor assay for TSH and TSH-displacing antibody.

Authors:  P Kotulla; H Schleusener
Journal:  J Endocrinol Invest       Date:  1981 Apr-Jun       Impact factor: 4.256

8.  Binding of solubilized human TSH-receptor protein by peripheral blood lymphocytes of patients with Graves' disease.

Authors:  B Wenzel; K W Wenzel; P Kotulla; H Schleusener
Journal:  J Endocrinol Invest       Date:  1981 Apr-Jun       Impact factor: 4.256

9.  Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves' disease.

Authors:  C Marcocci; L Chiovato; S Mariotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.